Patients with hereditary angioedema using deucrictibant as an on-demand treatment for attacks achieved onset of symptom ...

Please provide your email address to receive an email when new articles are posted on . Children took daily doses of berotralstat that ranged from 78 mg to 150 mg. There were no grade 3 or 4 adverse ...

An antisense oligonucleotide therapy showed efficacy as a prophylactic treatment for hereditary angioedema (HAE), the phase III OASIS-HAE trial showed. The least-squares mean time-normalized HAE ...

The study met its primary endpoint demonstrating a significant reduction in the rate of HAE attacks in patients who received donidalorsen vs placebo. Topline results were announced from a phase 3 ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A single dose of ...

Even if you’re doing everything you can to avoid an episode of hereditary angioedema (HAE) — dodging injuries, preventing respiratory illnesses, taking medication — it’s not always possible to ward ...

Posters highlight clinically meaningful improvement in HAE symptoms observed in the first hours after treatment with PHVS416 (deucrictibant immediate-release capsules) as compared to placebo “When ...

If approved, berotralstat would be the first oral prophylactic HAE therapy for children under the age of 12. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug ...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that it presented real-world data from US patient surveys that assessed the ...

Hereditary angioedema (HAE) is a rare genetic condition that causes episodes of pronounced swelling in parts of the body including the face, hands, feet, genitals, abdomen, and airways. While HAE ...

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for ...